WHWK:NASDAQ, Whitehawk Therapeutics, Inc.
WHWK stock overview
Whitehawk Therapeutics, Inc. (WHWK:NASDAQ) closed at $3.21 on October 23, 2026,
down 1.23% on the day.
The stock trades 41.6% below its 52-week high of $5.50
and 62.9% above its 52-week low of $1.97.
Over the past year, it gained 33.2%.
Whitehawk Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $3.21
- Day change
- -1.23%
- Volume
- 222,609
- Average volume
- 364,834
- Market cap
- 182M+
- 52-week range
- $1.97 – $5.50
- 50-day average
- $4.03
- 200-day average
- $3.82
Price action over the past year
In 252 trading sessions since October 23, 2025, WHWK closed higher on 121 days (48%).
Its best day was May 13, 2026 (+25.77%) and its worst was March 27, 2026 (-11.48%).
The stock moved 10% or more in a single session 6 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
WHWK news
-
Oct 7, 2026:
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
-
Oct 1, 2026:
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
-
Sep 14, 2026:
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
-
Sep 10, 2026:
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
-
Sep 2, 2026:
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
-
Aug 28, 2026:
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
-
Aug 26, 2026:
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
-
Aug 13, 2026:
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
About Whitehawk Therapeutics, Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
Similar stocks
Find more stocks like WHWK with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.